Stimulator of interferon genes (STING) is an adaptor protein that plays an 
important role in the activation of type I interferons in response to cytosolic 
nucleic acid ligands. Recent evidence indicates involvement of the STING pathway 
in the induction of antitumor immune response. Therefore, STING agonists are now 
being extensively developed as a new class of cancer therapeutics. However, 
little is known about the consequences of activated STING-mediated signaling in 
cancer cells on the efficacy of the antitumor treatment. It has been shown that 
activation of the STING-dependent pathway in cancer cells can result in tumor 
infiltration with immune cells and modulation of the anticancer immune response. 
Understanding the function of STING pathway in cancer cells might provide 
important insights into the development of effective therapeutic strategies. 
This review focuses on the role of STING pathway in cancer cells, the largely 
unknown topic that has recently emerged to be important in the context of 
STING-mediated antitumor responses.